- Home
- JFIN vs REPL Comparison
JFIN vs REPL Comparison
Compare JFIN & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFIN
- REPL
- Stock Information
- Founded
- JFIN 2011
- REPL 2015
- Country
- JFIN China
- REPL United States
- Employees
- JFIN N/A
- REPL N/A
- Industry
- JFIN Finance: Consumer Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- JFIN Finance
- REPL Health Care
- Exchange
- JFIN Nasdaq
- REPL Nasdaq
- Market Cap
- JFIN N/A
- REPL 851.0M
- IPO Year
- JFIN 2019
- REPL 2018
- Fundamental
- Price
- JFIN $13.59
- REPL $9.75
- Analyst Decision
- JFIN
- REPL Strong Buy
- Analyst Count
- JFIN 0
- REPL 6
- Target Price
- JFIN N/A
- REPL $20.00
- AVG Volume (30 Days)
- JFIN 249.1K
- REPL 658.1K
- Earning Date
- JFIN 03-27-2025
- REPL 05-15-2025
- Dividend Yield
- JFIN 6.37%
- REPL N/A
- EPS Growth
- JFIN N/A
- REPL N/A
- EPS
- JFIN 2.73
- REPL N/A
- Revenue
- JFIN $794,759,901.00
- REPL N/A
- Revenue This Year
- JFIN N/A
- REPL $31.16
- Revenue Next Year
- JFIN N/A
- REPL N/A
- P/E Ratio
- JFIN $5.12
- REPL N/A
- Revenue Growth
- JFIN 6.11
- REPL N/A
- 52 Week Low
- JFIN $4.00
- REPL $4.92
- 52 Week High
- JFIN $16.22
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- JFIN 61.77
- REPL 28.07
- Support Level
- JFIN $11.60
- REPL $10.17
- Resistance Level
- JFIN $16.22
- REPL $10.78
- Average True Range (ATR)
- JFIN 1.38
- REPL 0.62
- MACD
- JFIN 0.18
- REPL -0.12
- Stochastic Oscillator
- JFIN 59.91
- REPL 5.56
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.